Stentys attracts experienced medical officer to work on new-generation stent
This article was originally published in Clinica
Stentys, a French company focused on developing a “next-generation” drug-eluting stent, has appointed vascular device specialist René Spaargaren as chief medical officer. Dr Spaargaren joins the Paris-based company from vascular and neurovascular device maker ev3 (Minnesota) where, as vice-president of international clinical affairs, he drove product development and launches. His appointment will help to establish the usability for physicians of the firm’s coronary artery bifurcation stent (currently undergoing clinical evaluation and expected to enable patients to avoid open-chest surgery), said CEO and co-founder Gonzague Issenmann. Dr Spaargaren has held senior positions with Boston Scientific (medical director, Europe) and Medtronic’s cardiac assist venture (clinical manager, Europe).